---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000779"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:06:38.956012+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agenus Q1 net loss $70.9M; botensilimab combo shows 63% 12-month OS in colorectal cancer

## Summary
- Revenue $22.9M, net loss $70.9M ($0.22 EPS) vs loss $50.6M ($0.19 EPS) year ago.
- Cash & investments $189.2M at March 31; raised $13.6M in ATM sales post-quarter.
- Botensilimab/balstilimab: 63% 12-month OS in non-MSI-H CRC (vs 25% SOC); 33% ORR in platinum-resistant ovarian cancer.
- FDA granted Fast Track for botensilimab/balstilimab in non-MSI-H/dMMR mCRC without active liver metastases.
- Distributed ~5M MiNK shares (NASDAQ: INKT) as dividend to AGEN shareholders on May 1, 2023.

## SEC filing metadata
- accession: 0001157523-23-000779
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000115752323000779/0001157523-23-000779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000115752323000779/a53395899.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000779
- JSON: https://secwatch.observer/filing/0001157523-23-000779.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000779.txt

## Key facts
- Earnings Releases
  AGENUS INC reported the first quarter ended March 31, 2023 results: revenue $22.9 million, net income $70.9 million, EPS $0.22 per share.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $22.9 million
  - Net income: $70.9 million
  - EPS: $0.22 per share
  - Result: reported results
  source text: For the first quarter ended March 31, 2023, we recognized revenue of $22.9 million and incurred a net loss of $70.9 million (including non-cash expenses of $24.9 million) or $0.22 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098972/000115752323000779/0001157523-23-000779-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.